Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma.
Schmidt-Wolf
I G
IG
Huhn
D
D
Neubauer
A
A
Wittig
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D002478:Cells, Cultured; D002985:Clinical Protocols; D003110:Colonic Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000009:adverse effects; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D015851:Interleukin-7 / Q000009:adverse effects / Q000096:biosynthesis / Q000235:genetics*; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000378:metabolism / Q000637:transplantation*; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010166:Palliative Care; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000096:biosynthesis; D016879:Salvage Therapy
D007375:Interleukin-1; D007376:Interleukin-2; D015851:Interleukin-7; D011993:Recombinant Fusion Proteins; D007371:Interferon-gamma